Clinical Trials Update:&nbsp;Feb. 11, 2005
41436
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:
117982
Robert B. Saper, MD, MPH ; Stefanos N. Kales, MD, MPH ; Janet Paquin, PhD ; Michael J. Burns, MD ; David M. Eisenberg, MD ; Roger B. Davis, ScD ; Russell S. Phillips, MD.
592462
roundup Plus: PC shipments up, but revenue less so, study says...BEA mobilizes corporate data...Web services outfits merge...Microsoft sets holiday Xbox bundle...PalmSource settles Digeo patent suit.
637665
roundup Plus: RIM touts BlackBerry with Wi-Fi...HP to sell Voltaire's InfiniBand switch...PC shipments up, but revenue less so, study says.
402115
Two drugs provide good results in preliminary trials.
438501
Here's what a newly approved drug looks like.
521918
The new Genentech, Inc., cancer drug Avastin appears to extend survival for patients with colorectal cancer by nearly two months, US National Cancer Institute researchers have concluded.
320923
ASK YOUR DOCTOR ABOUT VIOXX . . . but not for the reasons Merck &amp; Co. recommends. Last week a Food and Drug Administration (FDA) study found a link with heart attacks, and several large health insurers said
450771
NEW YORK  - In general, chemotherapy  appears to increase the risk of stroke in patients with breast  cancer. However, researchers report in the October 20th issue  of the Journal of the National Cancer Institute.
563594
The Kootenai Medical Center's North Idaho Cancer Center will begin offering some patients the option of taking part in trials of experimental cancer drugs, starting in January.
454422
roundup Plus: IBM launches business research group...Verbatim to make discs with HP labeling feature...SWsoft teams with Acronis to boost virtual servers...Dell, Topspin tout InfiniBand clusters.
554707
NEWS: In 2002, weeks before President Bush announced a plan to protect African babies from AIDS, top US health officials were warned that research about the drug, nevirapine, was flawed
266395
New publications, experiments and breakthroughs in biotechnology--and what they mean.
757229
Genzyme Corp. of Cambridge and German partner Bayer Schering Pharma AG said they have begun phase 3 trials of their cancer drug Campath to treat multiple sclerosis. The companies said they plan on reporting phase 2 results Oct. 14. After phase 3, they hope to seek US regulatory approval in 2011 to market the drug, also known as alemtuzumab, to ...
539492
Neurocrine updates investors on the status of its top drugs.
93775
Encouraging phase II results of a trial to test the efficacy of a malaria vaccine for young children is published in this week&#39;s issue of THE LANCET (pp 1380, 1411).
767081
Â· Lancet fast-tracks research sponsored by drug firm Â· Health advisers consider vaccinating older women